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1. Introduction 
Sneddon’s syndrome is a rare disease defined by generalised livedo racemosa of the skin 
and recurrent stroke. It was first described in a patient in 1960 by Champion and Rook 
(Champion and Rook, 1960), and five years later Sneddon IB suggested the association of 
livedo and stroke in six new cases (Sneddon, 1965). Sneddon’s syndrome may be 
differentiated according to the presence or absence of circulating antiphospholipid (aPL) 
antibodies: aPL-positive Sneddon’s syndrome and aPL-negative or seronegative Sneddon’s 
syndrome (Ulukaya et al, 2008). Approximately 40% of Sneddon’s syndrome patients have 
aPL antibodies, raising the question of whether Sneddon’s syndrome overlaps with primary 
antiphospholipid antibody syndrome (APS) and systemic lupus erythromatosis (SLE) 
(Geschwind et al, 1995). APS or Hughes syndrome is a systemic autoimmune disease 
consisting of thrombosis (venous and/or arterial) and/or pregnancy failure in association 
with persistent production of aPL antibodies (aPL): anticardiolipin antibodies (aCL) of 
immunoglobulin G (IgG) and IgM class, lupus anticoagulant (LA) causing prolongation of 
activated partial thromboplastin time, and/or B2 glycoprotein I antibodies of IgG and IgM 
class. Although there are overlapping manifestations between Sneddon’s syndrome and 
APS, namely livedo and recurrent thrombotic events, their relationship remains 
controversial (Francès et al, 1999). Some authors consider aPL-positive Sneddon’s syndrome 
as a primary APS while others support the idea that aPL antibodies are involved in the 
pathogenesis of Sneddon’s syndrome (Fetoni et al, 2000; Hannon et al, 2010; Kalashnikova et 
al, 1990; Luvisotto Marinho et al, 2007; Sumi et al, 1999). In this article, we will review the 
clinical and neuropsychological features of Sneddon’s syndrome and APS and focus on the 
seronegative Sneddon’s syndrome although the majority of the published data does not 
make a distinction between seronegative and aPLpositive Sneddon’s syndrome. 
2. Sneddon’s syndrome 
Sneddon’s syndrome occurs usually among women in their third decade. Most cases are 
sporadic, but some rare familial cases have been reported (Pettee et al, 1994; Rebollo et 
al,1983; Scott et al, 1986). Both autosomal dominant and recessive transmissions were noted 
(Mascarenhas et al, 2003). Livedo racemosa, introduced for the first time in 1907 by 
Ehrmann, is characterized by a striking violaceous netlike patterning of the skin similar to 
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the familiar livedo reticularis, from which it differs by its location (more generalized and 
widespread, non-infiltrated, found not only on the limbs but also on the trunk and/or 
buttocks), its shape (irregular, broken, circular segments) and its persistence with variation 
of ambient temperature (Uthman and Khamashta, 2006).  
The pathogenesis of Sneddon’s syndrome remains unclear and the proposed etiology varies 
from a hypercoagulate state to a primary inflammatory vasculopathy (De Reuck, 2009). The 
etiology of Sneddon’s syndrome is not completely understood. Skin biopsies often fail to yield 
diagnostic arterial lesions. Selection of the correct biopsy site (seemingly uninvolved skin at 
the center of a livedo racemosa area), adequate biopsy size (1 to 2 cm), and serial sections are 
essential for detection of relevant vascular pathology (Zelger et al, 1992). Sensitivity of these 
biopsies increased from 27% with one biopsy to 80% with 3 biopsies (Wohlrab et al, 2001). 
Sepp et al, (1995) studied skin specimens of 18 patients with Sneddon’s syndrome, and 
reported that CD3+, UCHL-1+ (ubiquitin carboxy-terminal hydroxylase L1) and HLA-DR+ 
cells constituted a significant proportion of the inflammatory infiltrate in the early stages, 
whereas in later stages, endothelial cells and leukocytes were scarce. These data confirmed the 
hypothesis that Sneddon’s syndrome starts as an inflammatory and possibly immunologically 
mediated disorder, leading to a migration and proliferation of smooth cells of small arteries, 
resulting in a partial or complete narrowing of the vessel. Others studies did not find 
inflammatory abnormalities at skin biopsies (Wohlrab et al, 2001). In few studies, brain 
biopsies have not shown vasculitic or thrombotic changes (Boortz-Marx et al, 1995; Devuyst et 
al, 1996; Geschwind et al, 1995). The small number of pathological studies makes it difficult to 
determine whether Sneddon’s syndrome is inherently an inflammatory vasculitic or occlusive 
thrombotic disease (Hannon et al, 2010).  
Diagnosis of Sneddon’s syndrome is based on the presence of skin livedo and neurological 
symptoms related to stroke. Neurological manifestations of Sneddon’s syndrome range 
from motor deficit, aphasia, headache, vertigo and seizures (table 1) (Fetoni et al, 2000; 
Stockhammer et al, 1993; Tourbah et al, 1997). Intracerebral, subarachnoid and 
intraventricular hemorrhages have also been reported (Bayrakli et al, 2010; Kraemer et 
Berlit, 2008; Luvisotto Marinho et al, 2007). Few case reports have described seronegative 
Sneddon’s syndrome (Duval et al, 2009; Hanon et al, 2010; Luvisotto Marinho et al, 2007). To 
our knowledge, only two series have analyzed both patients suffering from Sneddon’s 
syndrome with and without aPL (Francès et al, 1999; Tourbah et al, 1997). No correlation 
was noted between severity of neurological outcome and the posivity of aPL (Tourbah et al, 
1997). No difference beetwen these two subgroups concerning the mean age at first clinical 
cerebral event was observed (Francès et al, 1999). Seronegative Sneddon’s syndrome seems 
to have larger fishnet pattern of livedo racemosa, less frequent seizures and slower 
progression (Francès et al, 1999; Hannon et al, 2010). 
Sneddon’s syndrome is a progressive condition, and the long-term functional status is usually 
related to the cumulative burden of repeated ischemic infarcts leading to mental deterioration 
and dementia. Prognosis of untreated Sneddon’s syndrome is poor, and about half of the 
patients suffer long-term disability (Francès et al, 1999; Tourbah et al, 1997). The differential 
diagnosis should include other neurological diseases associating cutaneous alterations of 
vascular origin and stroke. One of these rare entities has been described by Divry and Van 
Bogaert in 1946 and called diffuse leptomeningeal angiomatosis. Divry Van Bogaert’s 
syndrome (DVB) is characterised by recurrent strokes in young patients especially children, 
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preceded by livedo localized mainly on the face and distal extremities. Skin biopsies show no 
vasculitis, but an increased number of dermal vessels with smooth muscles fibers disposed 
around them is seen. Cerebral CT scan and MRI in DVB syndrome can be identical to 
Sneddon’s syndrome. Cerebral angiography showing corticomeningeal angiomatosis with 
collateral vascular anastomosis and narrow and helicine vessels in the midcerebral arteries 
confirms the diagnostic of Divry Van Bogaert’s disease (Guillot et al, 1994). Dego’s disease also 
known as malignant atrophic papulosis, first described in 1942 by Degos, is an another rare 
syndrome, very similar to Sneddon’s syndrome and characterised by thrombo-occlusive 
vasculopathy affecting the skin and various internal organs. In the skin, Dego’s disease 
initially manifests with erythematous, pink or red papules. These papules heal to leave scars 
with pathognomonic, central, porcelain white atrophic centers and a peripheral telangiectatic 
rim leading to atrophy and ulcers of the skin. In the systemic form, gastrointestinal and central 
nervous system involvements are the most frequent complications (Jura et al, 1994).  
 
Neurological signs Stockhammer et al, 1995 
17 cases 
Tourbah et al, 1997 
26 cases 
Fetoni et al, 2000  
9 cases 
Motor deficit 70 % 73% 66% 
Aphasia 35% 50% - 
Cognitives disorders - 27% 11% 
Neuro-ophtalmic signs 29% 30% 22% 
Sensitives signs 76% 19% - 
Seizures 17% 19% 11% 
Headache 82% 38% - 
Vertigo 47% 11% 11% 
Pseudo-bulbar syndrome 11% 11% - 
Table 1. Neurological features of Sneddon’s syndrome in different series 
Limited data are available concerning cognitive dysfunction in Sneddon’s syndrome. After 
several years of evolution, 77% of patients with Sneddon’s syndrome exhibit signs of mild 
cognitive vascular impairment with loss of concentration ability, memory disturbances and/or 
frontal type of behavioral changes (De Reuck, 2009). To date, only three reports have 
mentioned a detailed psychometric study showing marked deficits in the tests of memory, 
concentration, attention, visual perception and visuo-spatial construction (Hannon et al, 2010; 
Montagné de la Roque and al, 2006; Weissenborn et al., 1996). Cognitive disorders especially 
impairments in concentration and memory are often observed in Sneddon’s syndrome 
without any history of cerebral stroke (Adair et al, 2001; Maamar et al, 2007; Weissenborn et al, 
1996; Wohlrab et al, 2006). Evolution of Sneddon’s syndrome includes continued cognitive 
decline and progression of leukoencephalopathy, causing subcortical vascular dementia in 
23% of cases and resulting often in disability to get a correct employment (kalashnikova et al, 
1990; Kraemer et al, 2008; Maamar et al, 2007; Rebollo et al, 1983; Stephen et Ferguson, 1982; 
Stockhammer et al, 1993; Weissenborn et al, 1996). In 2003, Boesch et al, did not find this 
classical pattern of Sneddon’s syndrome in a prospective six year follow up study. Results of 
their study suggest in contrast a low incidence of territorial stroke and dementia but outline 
progressive leucencephalopathy. Dementia is caused by the recurrence of ischemic, rarely 
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hemorrhagic stroke and it is preceded in half of cases by a transient ischemic attack. The 
process that leads to neurological dysfunction seems to be both structurally destructive and 
functionally impairing with neuronal loss (Liberato and Levy, 2007). Rarely, dementia 
represents the initial symptom of Sneddon’s syndrome (Flöel et al, 2002; Maamar et al, 2007).  
In Sneddon’s syndrome, stroke affects mainly medium-sized arteries and are seen 
particularly in the territory of the middle and posterior cerebral artery (Maamar et al, 2007; 
Stockhammer et al, 1993). Infarct of the vertebral basilar territory was present in 47% of 
cases among 17 patients described by Stockhammer et al in 1993. Basal ganglia are usually 
normal (Tourbah et al, 1997). Leucoencephalopathy constitutes a classical MRI finding in the 
evolution of Sneddon’s syndrome, localized usually in the posterior subcortical white matter 
(Boesch et al, 2003; Tourbah et al, 1997). As reported by Tourbah et al in 1997 and 
Weissenborn et al in 1996, the extent of cerebral infarcts is significantly correlated with the 
severity of cognitive disorders. The progressive cognitive impairment in Sneddon’s 
syndrome is also, correlated to the degree of white matter changes and the presence of 
lacunar infarcts (De Reuck, 2009). Moreover the cognitive dysfunction score is related to the 
brain atrophy score (Weissenborn et al, 1996) and the degree of physical impairment 
(Tourbah et al, 1997; Weissenborn et al, 1996). In contrast, the duration of the disease seems 
to have no influence on the degree of cognitive dysfunction (Weissenborn et al, 1996).  
There is no current therapeutic consensus well established in the management of Sneddon’s 
syndrome. In the absence of controlled studies, treatment of Sneddon's syndrome remains 
empirical. Antiplatelets agents and anti-coagulant treatment are most often used. 
Corticosteroids, azathioprine and cyclophosphamid were administered by some with little 
success (Zelger et al, 1993). Few reports noted potential therapeutic options for cognitive 
disorder in Sneddon’s syndrome patients, but generally, theses studies did not demonstrate 
objective improvements on neuropsychological evaluation. Kume et al (1996) treated a 24-
year-old man using cyclophosphamide, prednisolone with improvement of psychiatric 
symptoms and a decreased anticardiolipin level. However, mental abilities remained 
subnormal. No objective neuropsychological testing was performed. Flöel et al (2002) also 
reported a 29-year-old woman with Sneddon’s syndrome who continued to decline 
cognitively when treated with steroids, azathioprine and aspirin. The therapy was switched 
to aspirin plus clopidogrel and the regimen stabilized cognitive function on 
neuropsychological tests. One other study confirmed subsequent improvement in subjective 
and objective memory and emotional status in a 46 years old woman suffering from 
seronegative Sneddon’syndrome using a treatment with cyclophosphamide during 8 
months. Authors have suggested therefore that cyclophosphamide should be considered 
among first line treatment options for patients with Sneddon’s syndrome and cognitive 
impairment (Hannon et al, 2010).  
3. Antiphospholipid antibody syndrome 
APS is an autoimmune disorder in which autoantibody production can lead to a 
hypercoagulable state, pregnancy failure and/or a multitude of other systemic 
manifestations. APS has previously been divided into primary and secondary forms, these 
last are associated with other connective tissue diseases, mainly SLE. However, this 
distinction was abandoned in the new classification (The 2006 Sydney Revised Classification 
Criteria based on the preliminary international Sapporo 1999) (table 2).  
www.intechopen.com
 
Cognitive Disturbances in Sneddon and Antiphospholipid Syndromes 
 
119 
Diagnostic criteria for antiphospholipid syndrome 
Clinical criteria 
- Vascular thrombosis: one or more episodes of arterial, venous or small vessel thrombosis 
in any tissue or organ (confirmed by imaging or histopathology) 
- Recurrent pregnancy loss (1 > 10 weeks’ gestation, or 3 < 10 weeks’ gestation) or one or 
more premature births due to pregnancy complications 
Laboratory criteria 
- Lupus anticoagulant in plasma on two occasions at least 12 weeks apart 
- Anticardiolipin antibodies of IgG and/or IgM isotype on two occasions at least 12 weeks 
apart 
- Anti-b2-GPI antibody of IgG or IgM isotype on two occasions at least 12 weeks apart 
 
Antiphospholipid syndrome is considered to be definitely present when at least one clinical criterion 
and one laboratory criterion are met. Ig: immunoglobulin; GPI: glycoprotein-I. 
Table 2. Diagnostic criteria for APS based on the 2006 Sydney update of the 1999 Sapporo 
classification (Austin and Cohen, 2010) 
In addition to peripheral thrombosis affecting any size of vessels, a variety of clinical 
manifestations is reported: skin disease, cardiac, pulmonary and renal involvement, 
haematologic manifestations and wide spectrum of neurological disorders (Mayer et al, 
2010). Thrombocytopenia is variably present. Neurological features of APS are dominated 
by the presence of ischaemic stroke which is the most common neurological manifestation 
(>50% of CNS complications). Other reported neurological manifestations include cerebral 
venous thrombosis, migraines, seizures, chorea, transverse myelitis and multiple sclerosis 
like syndrome (Austin and Cohen, 2010). Two clinical subgroup of APS are now identified. 
Catastrophic APS is characterized by life-threatening acute multiple organ failure from 
extensive microvascular thrombosis (‘thrombotic storm’). Laboratory evidence of 
disseminated intravascular coagulation can occur. Suggested precipitants of this syndrome 
include infection, oral contraceptives, surgery and withdrawal of anticoagulation. The 
mortality rate is approximately 50%. The second subset is called Seronegative APS which 
includes patients exhibiting clinical manifestations of APS, without any recognized aPL. 
Subsequent repeat aPL testing can be positive (Austin and Cohen, 2010). 
Several studies suggest an association between aPL and cognitive dysfunction based on 
microthrombotic events or vasculopathy. The underlying mechanism of cognitive deficits is 
not clear. Hypothesis of recurrent cerebral ischemia or a direct effect of aPL disrupting 
neuronal function, like it is shown in experimental studies on animal models has been 
issued (Katzav et al, 2001).  
The majority of studies concerning cognition in APS patients included also cases of SLE with 
aPL. Although there have been no studies to date that have accurately identified the 
frequency of neuropsychological manifestations in APS, studies in SLE patients with or 
without aPL provide excellent models for the analysis of neurocognitive dysfunction (Erkan 
et al, 2011).  
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Results of several series indicated that a majority of patients with APS (combined primary 
and SLE-related APS) had cognitive deficits affecting like in Sneddon’s syndrome, mainly 
memory, concentration, complex attention and verbal fluency (Tektonidou et al, 2006).  
Two studies have examined the cognitive function in primary APS patients compared to 
controls or other patient groups. Jacobson et al (1999) examined neuropsychological 
functioning in 27 young patients with elevated levels (>10 IU) of aCL IgG. Compared with 
27 age and education-matched controls, there were group differences in domain scores of 
working memory, executive functions, verbal learning, memory and visuospatial 
functioning. The overall frequency of impaired neuropsychological performance was greater 
among individuals with aPL than controls (33% versus 4% respectively) suggesting subtle 
neurological involvement. Tektonidou et al (2006), examined 39 patients with primary APS, 
21 patients with SLE-related APS and 60 healthy controls using a neuropsychological 
battery measuring attention, learning, memory, executive functions and visuospatial skills 
and depression. Results indicated that 42% of the 60 patients with APS (combined primary 
and SLE-related APS) had cognitive deficits compared with 18% of healthy controls with 
deficits most common in complex attention and verbal fluency. There was no difference in 
cognitive performance between patients with primary APS and those with SLE-associated 
APS (Erkan et al, 2011). Maeshima et al (1992) analyzed 21 SLE patients with aPL and noted 
abnormal findings in verbal learning and visuoconstructive skills in 72% of patients. 
Otherwise, LA positive patients had poor results in verbal memory, attention, cognitive 
flexibility and psychomotor speed tests in comparison with LA negative patients (Denburg et 
al, 1997; Leritz et al, 2000; Menon et al, 1999). Positive LA test has been found to be more 
frequent (15,7%) in SLE patients with cognitive disorder compared to the SLE patients without 
cognitive impairment (Sanna et al, 2003). Hanley et al (2004) reported also that patients with 
persistently elevated IgG aCL had a significant decline in psychomotor speed, while those 
with persistently elevated IgA aCL had decline in conceptual reasoning and executive ability.  
Chapman et al (2002) studied 23 patients with primary APS and found that 13 (56%) fulfilled 
criteria for vascular dementia. Patients with dementia were older, had more CT scan 
abnormalities and more electroencephalography changes than those without dementia. The 
“Euro-Phospholipid consortium”, did not find the same results in their cohort of 1000 APS 
patients, only 25 cases (2,5%) had vascular dementia. 
Other studies of primary APS or asymptomatic aPLpositive patients have shown that 
cognitive deficits may be present independent of any history of known central nervous 
system involvement. These patients may complain of difficulty with memory, attention, and 
concentration; or the dysfunction may be subclinical and apparent only with 
neuropsychological testing (Austin and Cohen, 2010; Erkan et al, 2011). Erkan et al,(2010) in 
a 10-years follow-up study of 66 patients with primary APS, found that 3 patients (<30 years 
old) developed dementia, independently of the presence of cerebrovascular accidents. In a 
recent study of 25 patients with APS followed between 1983 and 2003, previous history of 
stroke and/or transient ischemic stroke was present respectively in only 11 and 2 patients, 
whereas, silent brain infarcts were present in 14 (47%) patients. Dementia was the 
presenting manifestation of the APS in 11 (37%) patients (Gomez-Puerta et al, 2005).  
Although relatively few studies have been conducted, neuroimaging abnormalities have 
been reported in primary APS patients presenting with high levels of overt clinical 
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neurological and psychiatric syndromes. Infarcts and hyperintense white matter foci are the 
most common abnormalities seen on cerebral CT scan or MRI in APS patients. However, 
most neuroimaging studies reported include patients with both APS and lupus (Erkan et al, 
2011). 
Cortical and subcortical infarcts are the most frequent findings. Gomez-Puerta et al (2005) 
studied neuroimaging findings in combined lupus/APS group of 30 patients and reported 
cortical infarcts in 63% of patients, subcortical infarcts in 30%, basal ganglia infarcts in 23% 
and signs of cerebral atrophy in 37%. Other ischaemic lesions such as lacunar and 
periventricular infarcts are not uncommon. Cerebral atrophy and white matter lesions 
(leukoaraiosis), similar to the lesions found in Binswanger’s disease, are often seen, 
especially in elderly APS patients(Gomez-Puerta et al, 2005). Chapman et al (2002) reported 
that only half of their demented APS patients had abnormal CT scans and suggested that the 
demented APS patients with normal CT scans may have micro-lesions. Of those with 
dementia, six had generalized atrophy and seven of the scans had focal lesions consistent 
with vascular pathology. 
Only one study of primary APS patients has investigated MRI abnormalities and their 
relation to cognitive dysfunction. Significant correlation between cognitive dysfunction and 
the presence of white matter lesions was reported in APS patients with and without central 
nervous system involvement. In 23 APS patients with central nervous system involvement, 
12 patients (52%) had white matter lesions with 100% in the periventricular area. Of the 36 
APS patients without central nervous system involvement, 8 (22%) of the patients had white 
matter lesions with 88% in the periventricular location. Cognitive deficits were identified in 
7 of those patients. A significant correlation was reported between cognitive deficits and 
white matter lesions across the two groups (Tektonidou et al, 2006). MRI spectroscopy is a 
predictive tool when compared to conventional parenchymal MRI in patients with APS, 
cognitive decline and normal brain MRI. These results corroborate the impression of 
subclinical neuronal damage induced by disease activity. When multimodal imaging 
techniques are used assessing not only neurometabolic patterns (MR spectroscopy), but also 
perfusion (SPECT) and morphological abnormalities (conventional MRI), the predictive 
power seems to be increased (Liberato and Levy, 2007). Kao et al (1999) studied 22 patients 
with primary APS with only mild neuropsychiatric manifestations (headache, depression, 
personality disorders, memory loss and cognitive function deficits) and normal brain MRI. 
They found that 16 (73%) of the patients had abnormal SPECT findings, mainly diffuse 
hypoperfusion lesions in cerebral cortex.  
Management of APS consists of initial therapy with low molecular weight heparin followed 
by oral anticoagulation. The duration of therapy depends on any additional risk factors, the 
location, severity, patient age and the relative risk of further thrombosis versus 
haemorrhage due to anticoagulation. Several strategies have been suggested for the 
treatment of dementia in APS patients. The management of atherogenic risk factors (i.e. 
diabetes, hypertension, hyperlipidaemia) is crucial. However, there is still no evidence that 
aspirin alone is effective in treating patients with a diagnosis of dementia. Some findings of 
improvement of cognitive function in the APS patients who underwent anticoagulation 
therapy have been reported (Hughes et al, 2001). In dementia associated with APS, 
anticoagulant treatment is recommended. Furthermore, the compliance of demented patients 
is usually poor, which requires special thought and attention (Gomez-Puerta et al, 2005). 
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In conclusion, seronegative Sneddon’s syndrome should be distinguished from Sneddon’s 
syndrome with aPL which should be considered as a subgroup of APS. Cognitive disorders 
in both Sneddon’ syndrome and APS seem to be similar affecting mainly memory, attention 
and concentration functions. They represent sometimes the inaugural symptom in a patient 
without any history of known ischemic stroke. Recurrent stroke may lead to multi-infarct 
dementia and early retirement in young people. Prognosis depends on early diagnosis. 
More subtle cognitive dysfunction can be shown. These troubles are related to posterior 
cortical infarcts or to leucoencephalopathy. Treatment should be aggressive in case of 
cognitive disturbances in Sneddon’s syndrome or APS.  
 
Fig. 1. Livedo racemoca affecting upper limbs in a patient with Sneddon’s syndrome 
(personal figure)  
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